Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06381154CT.gov Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer | — | Active Not Recruiting | — | — | — |
NCT06384560CT.gov Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) | — | Recruiting | — | — | — |
NCT05585320CT.gov A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05208762CT.gov A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05620134CT.gov Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | — | Active Not Recruiting | — | — | — |
NCT05365581CT.gov A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer | — | Recruiting | — | — | — |
NCT05086692CT.gov A Beta-only IL-2 ImmunoTherapY Study | — | Recruiting | — | — | — |
NCT04548752CT.gov Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | — | Active Not Recruiting | — | — | — |
NCT04389632CT.gov A Study of Sigvotatug Vedotin in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
Show 13 more trialsShow fewer
NCT04058964CT.gov Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer | — | Withdrawn | — | — | — |
NCT03871959CT.gov Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma | — | Completed | — | — | — |
NCT04060342CT.gov GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | — | Terminated | — | — | — |
NCT02757391CT.gov CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors | — | Terminated | — | — | — |
NCT03723915CT.gov Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer | — | Terminated | — | — | — |
NCT03006302CT.gov Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer | — | Completed | — | — | — |
NCT03331562CT.gov A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | — | Completed | — | — | — |
NCT03329950CT.gov A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | — | Completed | — | — | — |
NCT03095781CT.gov Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | — | Completed | — | — | — |
NCT02907099CT.gov Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer | — | Completed | — | — | — |
NCT02826486CT.gov Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients | — | Completed | — | — | — |
NCT02620423CT.gov Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | — | Completed | — | — | — |
NCT02376699CT.gov Safety Study of SEA-CD40 in Cancer Patients | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Mayo Clinic | P2 | B · 63 |
| Fluorouracilum | Jonsson Comprehensive Cancer Center | P4 | BBB |
| Docetaxel | Bristol-Myers Squibb | P2 | BBB |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P4 | BB |
| Irinotecan | Jonsson Comprehensive Cancer Center | P3 | BB |
| Capecitabine | Zhejiang University | P4 | BB |
| Olaparib | Lantern Pharma Inc. | P3 | BB |
| Daraxonrasib | Revolution Medicines, Inc. | P3 | BB |
| Irinotecan Sucrosofate | SWOG Cancer Research Network | P3 | BB |
+42 more in the Pancreatic Adenocarcinoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Pancreatic Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-pancreatic-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →